NASDAQ:ALKS Alkermes (ALKS) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free ALKS Stock Alerts $27.07 -0.18 (-0.66%) (As of 05:21 PM ET) Add Compare Share Share Today's Range$26.91▼$27.3350-Day Range$26.40▼$32.5652-Week Range$22.01▼$33.71Volume1.23 million shsAverage Volume1.90 million shsMarket Capitalization$4.52 billionP/E Ratio13.08Dividend YieldN/APrice Target$33.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Alkermes alerts: Email Address Alkermes MarketRank™ Stock AnalysisAnalyst RatingHold2.44 Rating ScoreUpside/Downside22.5% Upside$33.14 Price TargetShort InterestBearish8.43% of Shares Sold ShortDividend StrengthN/ASustainability-1.17Upright™ Environmental ScoreNews Sentiment0.53Based on 4 Articles This WeekInsider TradingSelling Shares$292,718 Sold Last QuarterProj. Earnings Growth-7.59%From $2.24 to $2.07 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.30 out of 5 starsMedical Sector339th out of 938 stocksPharmaceutical Preparations Industry149th out of 426 stocks 2.2 Analyst's Opinion Consensus RatingAlkermes has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 5 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $33.14, Alkermes has a forecasted upside of 22.5% from its current price of $27.05.Amount of Analyst CoverageAlkermes has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.43% of the outstanding shares of Alkermes have been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Alkermes has recently increased by 8.14%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlkermes does not currently pay a dividend.Dividend GrowthAlkermes does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlkermes has received a 60.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for physical health", "Antipsychotics", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alkermes is -1.17. Previous Next 2.0 News and Social Media Coverage News SentimentAlkermes has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Alkermes this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for ALKS on MarketBeat in the last 30 days. This is a decrease of -95% compared to the previous 30 days.MarketBeat Follows6 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alkermes insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $292,718.00 in company stock.Percentage Held by InsidersOnly 4.76% of the stock of Alkermes is held by insiders.Percentage Held by Institutions95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Alkermes are expected to decrease by -7.59% in the coming year, from $2.24 to $2.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alkermes is 13.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 141.63.Price to Earnings Ratio vs. SectorThe P/E ratio of Alkermes is 13.07, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 218.08.Price to Book Value per Share RatioAlkermes has a P/B Ratio of 3.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> About Alkermes Stock (NASDAQ:ALKS)Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Read More ALKS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALKS Stock News HeadlinesMarch 19, 2024 | insidertrades.comAlkermes plc (NASDAQ:ALKS) SVP Sells $292,717.70 in StockMarch 28, 2024 | nasdaq.comNoteworthy Tuesday Option Activity: ALKS, DKNG, VRTMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 21, 2024 | americanbankingnews.comAlkermes (NASDAQ:ALKS) Now Covered by Robert W. BairdMarch 20, 2024 | investing.comAlkermes exec sells over $290k in company sharesMarch 19, 2024 | msn.comBaird starts Alkermes at outperform, citing revenue streamMarch 19, 2024 | markets.businessinsider.comThe Analyst Verdict: Alkermes In The Eyes Of 4 ExpertsMarch 19, 2024 | americanbankingnews.comAlkermes plc (NASDAQ:ALKS) SVP Christian Todd Nichols Sells 10,417 SharesMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 18, 2024 | finance.yahoo.comInsider Sell: SVP, Chief Commercial Officer Christian Nichols Sells Shares of Alkermes PLC (ALKS)March 18, 2024 | americanbankingnews.comShort Interest in Alkermes plc (NASDAQ:ALKS) Expands By 6.5%March 15, 2024 | nasdaq.comALKS Factor-Based Stock AnalysisMarch 15, 2024 | finance.yahoo.comAlkermes (ALKS) Stock Moves -0.45%: What You Should KnowMarch 7, 2024 | finanznachrichten.deAlkermes plc: Alkermes Announces Appointment of Nancy S. Lurker to Board of DirectorsMarch 7, 2024 | finance.yahoo.comAlkermes Announces Appointment of Nancy S. Lurker to Board of DirectorsFebruary 27, 2024 | stocknews.comTop 3 Biotech Stocks to Consider for March ProfitsFebruary 21, 2024 | msn.comUBS Downgrades Alkermes (ALKS)February 21, 2024 | finance.yahoo.comWhy Alkermes (ALKS) is a Top Growth Stock for the Long-TermFebruary 21, 2024 | investorplace.comWall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024February 20, 2024 | msn.comAlkermes downgraded at UBS as stock nears 52-week highFebruary 20, 2024 | markets.businessinsider.comZealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial resultsFebruary 17, 2024 | finance.yahoo.comALKS Mar 2024 32.000 callFebruary 17, 2024 | finance.yahoo.comAlkermes Full Year 2023 Earnings: Beats ExpectationsFebruary 16, 2024 | markets.businessinsider.comAlkermes: Hold Rating Affirmed Amid EBITDA Growth and Strategic Acquisitions, Balanced by Cautious Sales OutlookFebruary 16, 2024 | finance.yahoo.comAlkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call TranscriptFebruary 16, 2024 | markets.businessinsider.comAlkermes: A Strong Buy on Path to Profitability, Strategic Capital Allocation, and Pipeline MomentumFebruary 15, 2024 | finance.yahoo.comAlkermes' (ALKS) Q4 Earnings & Revenues Surpass EstimatesSee More Headlines Receive ALKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today3/28/2024Next Earnings (Estimated)4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALKS CUSIPG0176710 CIK1520262 Webwww.alkermes.com Phone(531) 772-8000Fax781-890-0524Employees2,100Year Founded1987Price Target and Rating Average Stock Price Target$33.14 High Stock Price Target$39.00 Low Stock Price Target$25.00 Potential Upside/Downside+21.8%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$2.07 Trailing P/E Ratio13.14 Forward P/E Ratio12.15 P/E GrowthN/ANet Income$355.76 million Net Margins21.39% Pretax Margin25.34% Return on Equity16.10% Return on Assets9.15% Debt Debt-to-Equity Ratio0.24 Current Ratio2.86 Quick Ratio2.50 Sales & Book Value Annual Sales$1.66 billion Price / Sales2.73 Cash Flow$2.31 per share Price / Cash Flow11.80 Book Value$7.21 per share Price / Book3.77Miscellaneous Outstanding Shares167,080,000Free Float159,123,000Market Cap$4.55 billion OptionableOptionable Beta0.57 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Richard F. Pops (Age 62)Chairman & CEO Comp: $2.3MMr. Blair C. Jackson (Age 51)Interim Principal Financial Officer, Executive VP & COO Comp: $1.05MMr. David Joseph Gaffin (Age 52)Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary Comp: $1.08MMr. Iain Michael Brown (Age 55)Senior VP & CFO (Leave of Absence) Comp: $867.75kDr. Craig C. Hopkinson M.D. (Age 56)Executive VP of Research & Development and Chief Medical Officer Comp: $1.12MDr. Floyd E. Bloom M.D. (Age 87)Founder Comp: $57.73kMr. Samuel J. Parisi (Age 49)Interim Principal Accounting Officer & VP of Finance Mr. Thomas HarveyChief Information Officer & Senior VP of ITMs. Sandra CoombsSenior Vice President of Corporate Affairs & Investor RelationsMr. Michael J. Landine (Age 70)Senior VP of Corporate Development & Chief Risk Officer Comp: $750.46kMore ExecutivesKey CompetitorsEidos TherapeuticsNASDAQ:EIDXMadrigal PharmaceuticalsNASDAQ:MDGLAmicus TherapeuticsNASDAQ:FOLDIonis PharmaceuticalsNASDAQ:IONSGeronNASDAQ:GERNView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Bought 16,008 shares on 3/22/2024Ownership: 0.068%Healthcare of Ontario Pension Plan Trust FundSold 604 shares on 3/21/2024Ownership: 0.162%Christian Todd NicholsSold 10,417 sharesTotal: $292,717.70 ($28.10/share)Vanguard Group Inc.Bought 2,288,185 shares on 3/11/2024Ownership: 12.542%Twin Focus Capital Partners LLCBought 80,032 shares on 3/5/2024Ownership: 0.048%View All Insider TransactionsView All Institutional Transactions ALKS Stock Analysis - Frequently Asked Questions Should I buy or sell Alkermes stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ALKS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALKS, but not buy additional shares or sell existing shares. View ALKS analyst ratings or view top-rated stocks. What is Alkermes' stock price target for 2024? 9 analysts have issued twelve-month price objectives for Alkermes' stock. Their ALKS share price targets range from $25.00 to $39.00. On average, they anticipate the company's share price to reach $33.14 in the next year. This suggests a possible upside of 22.5% from the stock's current price. View analysts price targets for ALKS or view top-rated stocks among Wall Street analysts. How have ALKS shares performed in 2024? Alkermes' stock was trading at $27.74 on January 1st, 2024. Since then, ALKS shares have decreased by 2.5% and is now trading at $27.05. View the best growth stocks for 2024 here. Are investors shorting Alkermes? Alkermes saw a increase in short interest in March. As of March 15th, there was short interest totaling 14,080,000 shares, an increase of 8.1% from the February 29th total of 13,020,000 shares. Based on an average daily trading volume, of 1,840,000 shares, the days-to-cover ratio is presently 7.7 days. View Alkermes' Short Interest. When is Alkermes' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024. View our ALKS earnings forecast. How were Alkermes' earnings last quarter? Alkermes plc (NASDAQ:ALKS) posted its earnings results on Thursday, February, 15th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.51 by $0.29. The company had revenue of $377.50 million for the quarter, compared to analyst estimates of $362.78 million. Alkermes had a trailing twelve-month return on equity of 16.10% and a net margin of 21.39%. The business's revenue was up 23.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.02) EPS. What ETFs hold Alkermes' stock? ETFs with the largest weight of Alkermes (NASDAQ:ALKS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Subversive Mental Health ETF (SANE), iShares Neuroscience and Healthcare ETF (IBRN), Horizon Kinetics Medical ETF (MEDX), ALPS Medical Breakthroughs ETF (SBIO), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE) and Putnam BioRevolution ETF (SYNB). How will Alkermes' stock buyback program work? Alkermes announced that its Board of Directors has authorized a share repurchase plan on Thursday, February 15th 2024, which allows the company to buyback $400,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to buy up to 8.2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's leadership believes its shares are undervalued. What guidance has Alkermes issued on next quarter's earnings? Alkermes issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided EPS guidance of 2.800-2.800 for the period, compared to the consensus EPS estimate of 2.520. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.5 billion. What is Richard F. Pops' approval rating as Alkermes' CEO? 119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees. What other stocks do shareholders of Alkermes own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA). Who are Alkermes' major shareholders? Alkermes' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (12.56%), Vanguard Group Inc. (12.54%), Wellington Management Group LLP (9.12%), Hardman Johnston Global Advisors LLC (3.28%), RTW Investments LP (2.34%) and Primecap Management Co. CA (2.14%). Insiders that own company stock include Blair Curtis Jackson, Cato T Laurencin, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Richard F Pops, Shane Cooke and Wendy L Dixon. View institutional ownership trends. How do I buy shares of Alkermes? Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Alkermes have any subsidiaries? The following companies are subsidiares of Alkermes: Rodin Therapeutics.Read More This page (NASDAQ:ALKS) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.